Uemura T, Kawasaki S, Kawai H, Suga M, Maruyama S, Otani J, Morisue S, Yoshizane K, Morokoshi Y, Yamamoto M, Soda M
Dept. of Surgery, Himeji St. Mary's Hospital.
Gan To Kagaku Ryoho. 1996 Nov;23(13):1787-91.
Hepatic arterial infusion chemotherapy (HAIC) using implantable reservoir was performed for liver metastases of gastric cancer and the therapeutic effects were evaluated. A catheter was placed in the hepatic artery via left subclavian artery or by direct insertion at laparotomy. Cisplatin, adriamycin and 5-FU were administered. The liver metastases of gastric cancer without unresectable primary tumors and hepatectomy were divided into two groups, 16 HAIC cases (11 synchronous, 5 metachronous metastases) and 23 systemic chemotherapeutic cases (10 synchronous, 13 metachronous metastases). As a result, HAIC revealed a 62.5% response rate. The 50% survival period was 395 days for HAIC, and it was significantly prolonged compared with 198 days for systemic chemotherapy (p < 0.01). But 4 among 10 cases responding to HAIC showed subsequent extrahepatic spread of the disease. Treatment of these extra-hepatic lesions is difficult.
对胃癌肝转移患者采用植入式储液器进行肝动脉灌注化疗（HAIC），并评估其治疗效果。通过左锁骨下动脉或在开腹手术时直接插入的方式将导管置于肝动脉。给予顺铂、阿霉素和5-氟尿嘧啶。将无不可切除的原发性肿瘤且未行肝切除术的胃癌肝转移患者分为两组，16例接受HAIC治疗的患者（11例为同时性转移，5例为异时性转移）和23例接受全身化疗的患者（10例为同时性转移，13例为异时性转移）。结果显示，HAIC的有效率为62.5%。接受HAIC治疗患者的50%生存期为395天，与全身化疗的198天相比显著延长（p < 0.01）。但在10例对HAIC有反应的患者中，有4例随后出现肝外疾病扩散。这些肝外病变的治疗较为困难。
